These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18729095)

  • 1. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
    Groessl M; Hartinger CG; Dyson PJ; Keppler BK
    J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
    Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
    Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
    Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
    Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
    Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
    Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
    Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
    J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
    Bytzek AK; Boeck K; Hermann G; Hann S; Keppler BK; Hartinger CG; Koellensperger G
    Metallomics; 2011 Oct; 3(10):1049-55. PubMed ID: 21935553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
    Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
    J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
    Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
    J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
    Cetinbas N; Webb MI; Dubland JA; Walsby CJ
    J Biol Inorg Chem; 2010 Feb; 15(2):131-45. PubMed ID: 19707803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.
    Schluga P; Hartinger CG; Egger A; Reisner E; Galanski MS; Jakupec MA; Keppler BK
    Dalton Trans; 2006 Apr; (14):1796-802. PubMed ID: 16568190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
    Henke MM; Richly H; Drescher A; Grubert M; Alex D; Thyssen D; Jaehde U; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):58-60. PubMed ID: 19203540
    [No Abstract]   [Full Text] [Related]  

  • 18. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
    Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
    J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.
    Foteeva LS; Matczuk M; Pawlak K; Aleksenko SS; Nosenko SV; Karandashev VK; Jarosz M; Timerbaev AR
    Anal Bioanal Chem; 2017 Mar; 409(9):2421-2427. PubMed ID: 28116493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.